Dr. Adriane Fugh-Berman, a professor of pharmacology and physiology at Georgetown University Medical Center, welcomed the FDA approval. But she contended it was premature to declare that Journavx ...

Corrigan-Curay emphasized that Journavx could “mitigate certain risks associated with using an opioid for pain.” The FDA’s official account on X also tweeted the news — the agency’s ...

It will be sold under the brand name Journavx. “A new non-opioid analgesic ... acting director of the FDA’s Center for Drug Evaluation and Research, said in a news release.

The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

The approval was announced in an FDA press release, and it will be sold under the brand name Journavx by Vertex Pharmaceuticals. This painkiller's approval reflects the FDA’s commitment to ...

The FDA on Thursday approved Vertex Pharmaceuticals' Journavx to treat moderate to severe acute pain in adults. Acute pain is short-term pain often caused by surgery, accident or injury.

The FDA's approval process for Journavx included an evaluation of its safety and efficacy. Clinical trials demonstrated that the drug is effective in managing acute pain without the adverse ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain ... drug pipeline that involves winning FDA approval for multiple drugs across several ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for the treatment of moderate-to-severe pain that is a non-opioid and carries less risks of addiction than opioids. Journavx ...